文献速递乳腺癌

曲妥珠单抗对比观察用于HER2非扩增且循环肿瘤细胞阳性的早期乳腺癌:随机II期试验

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
PubMed 文献 · Ann Oncol · 2018-01-01

EORTC 90091-10093/BIG 1-12 Treat CTC研究是一项II期随机试验,纳入HER2非扩增、术后及(新)辅助化疗后每15ml血中≥1个循环肿瘤细胞(CTC)的早期乳腺癌患者,随机接受6周期曲妥珠单抗或18周观察。主要终点第18周CTC检出率在两组间无显著差异(P=0.765),独立数据监查委员会因主要终点无效建议停止入组。曲妥珠单抗未降低HER2非扩增非转移性乳腺癌患者的CTC检出率。

要点

  • 曲妥珠单抗未降低HER2非扩增早期乳腺癌第18周CTC检出率。
  • 研究因主要终点无效提前终止,1年iDFS两组数值均较高。
  • 曲妥珠单抗组未观察到2-4级心脏事件。

核心结论

  • 曲妥珠单抗不能降低HER2非扩增、非转移性乳腺癌患者的CTC检出率。

研究设计与样本

  • EORTC 90091-10093 BIG 1-12 Treat CTC为II期随机试验,在5个欧洲国家70家医院和6个CTC实验室开展。
  • 纳入中心确认HER2非扩增且术后及(新)辅助化疗后每15ml血中≥1个中心确认CTC(CellSearch®)的患者,1:1随机至6周期静脉曲妥珠单抗或18周观察。
  • 随机分层因素包括中心、当地确认的雌激素受体状态和辅助 versus 新辅助化疗。
  • 主要终点为第18周每15ml血中≥1个CTC的检出率;次要终点为无侵袭性疾病生存(iDFS)和心脏安全性。

主要发现

  • 2013年4月30日至2016年10月17日筛查1317例患者,95例(7.2%)可检测到CTC,63例(4.8%)随机分组:曲妥珠单抗组31例,观察组32例。
  • 58例可评估主要终点,每组29例;第18周时58例中9例仍可检测到CTC:曲妥珠单抗组5例,观察组4例(单侧Fisher精确检验,P=0.765)。
  • 独立数据监查委员会因主要终点无效建议停止进一步入组。
  • 数据库锁定时中位随访13个月(IQR 4-16.5);1年iDFS观察组为93.8%(95% CI 77.3-98.4),曲妥珠单抗组为84.8%(95% CI 63.4-94.2)。
  • 曲妥珠单抗组未观察到2-4级心脏事件。

临床怎么用

  • 对于HER2非扩增且CTC阳性的早期乳腺癌,不推荐使用曲妥珠单抗以清除CTC。

局限性

  • 研究因主要终点无效提前终止,随机样本量小(63例),事件数少。
  • 中位随访仅13个月,iDFS数据不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating tumor cells (CTCs) in women with high risk, HER2 nonamplified, early breast cancer. PATIENTS AND METHODS: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase II trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 nonamplified breast cancer and ≥1 centrally confirmed CTC per 15 ml of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1 : 1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation. Randomization was stratified for center, locally confirmed estrogen receptor status and adjuvant versus neoadjuvant chemotherapy. The primary end point was rate of detection of ≥1 CTC per 15 ml of blood at week 18. Secondary end points were invasive disease-free survival (iDFS) and cardiac safety. RESULTS: Between 30 April 2013 and 17 October 2016, 1317 patients were screened; 95 (7.2%) had detectable CTC(s), and 63 (4.8%) were randomized to trastuzumab (n = 31) or observation (n = 32). Fifty-eight patients were assessable for the primary end point, 29 in each arm. In 9 of the 58 patients, CTC(s) were still detected at week 18 : 5 in the trastuzumab and 4 in the observation arm (one-sided Fisher's exact test, P = 0.765). An Independent Data Monitoring Committee recommended stopping further accrual for futility for the primary end point. Median follow-up at database lock was 13 months (IQR 4-16.5). The 1-year iDFS was 93.8% (95% CI 77.3-98.4) in the observation versus 84.8% (95% CI 63.4-94.2) in the trastuzumab arm. No grade 2-4 cardiac events were observed in the trastuzumab arm. CONCLUSION: Trastuzumab does not decrease the detection rate of CTCs in HER2 nonamplified, nonmetastatic breast cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ignatiadis M, Litière S, Rothe F, et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol. 2018. PMID: 29893791. doi:10.1093/annonc/mdy211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。